Nebenwirkungen · Synagis
Synagis 50 mg/0.5 ml solution for injection Synagis 100 mg/1 ml solution for injection · Abschnitt 4.8 · PDF-Seite 4–5
HOS-090197 · Präparat HOS-084025
4 Undesirable effects in clinical studies* and post-marketing reports in paediatric patients MedDRA system organ Frequency ADR class Blood and lymphatic Uncommon Thrombocytopenia# system disorders Immune system disorders Not known Anaphylaxis, anaphylactic shock (in some cases, fatalities have been reported.)# Nervous system disorders Uncommon Convulsion# Respiratory, thoracic and Common Apnoea# mediastinal disorders Skin and subcutaneous Very common Rash tissue disorders Uncommon Urticaria# General disorders and Very common Pyrexia administrative site conditions Common Injection site reaction *For full study description, see Section 5.1 Clinical studies # ADRs identified from post-marketing surveillance
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-10-11T08:14:00Z · SHA-256 80b341ab31afe95db5c42fa61205421fb02b06bd1c5fb252bf6a42f441c92dde · Passage 0aed29b096a495810936ba4922e41f36592ea01c0cadb80e85b0a9268b5f9fb8 · Zeichen 1234–2571 im Abschnitt